why choose us

First received: February 15, 2023

Clinical Trial: Myositis Interstitial Lung Disease Nintedanib Trial

Study Status: Completed

Recruit Status: RECRUITING

Condition: Myositis Associated Interstitial Lund Disease (MA-ILD)

Study Type: INTERVENTIONAL


Official Title: Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients With Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized,

Brief Summary: This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD).Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung.This study will enroll a total of 134 participants across 15 clinical sites located in the United States.A subset of participants will be…

Read more